The inability to target Aβ in AD therapy and the intractability of neurodegenerative diseases have led many researchers to focus their research on tau protein, and many basic studies have demonstrated that the knockdown or inhibition of tau can reduce tau-associated pathological effects; thus, drugs targeting tau protein have attracted increasing attention. The gene discussed is MAPT; the disease is Alzheimer disease.